252 related articles for article (PubMed ID: 31941239)
1. [Effect of interferon or nucleos(t)ide analogs on hepatitis B-related hepatocellular carcinoma].
Liu ZH; Sun J
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):842-845. PubMed ID: 31941239
[TBL] [Abstract][Full Text] [Related]
2. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
3. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Hiramatsu N; Yamada R; Takehara T
J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
[TBL] [Abstract][Full Text] [Related]
5. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
6. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Triolo M; Della Corte C; Colombo M
Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
[TBL] [Abstract][Full Text] [Related]
7. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
8. [Mechanism relevant to hepatocellular carcinoma occurrence after negative conversion of viral DNA in treatment of chronic hepatitis B patients with nucleos(t)ide drugs].
Gao TJ; Han GY; Lu FM
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):905-909. PubMed ID: 31941249
[TBL] [Abstract][Full Text] [Related]
9. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Lim SG; Mohammed R; Yuen MF; Kao JH
J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
[TBL] [Abstract][Full Text] [Related]
10. [Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC].
Han C; Lai PP; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):827-830. PubMed ID: 31941235
[TBL] [Abstract][Full Text] [Related]
11. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.
Wei L; Kao JH
Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776
[TBL] [Abstract][Full Text] [Related]
12. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
[TBL] [Abstract][Full Text] [Related]
13. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
[TBL] [Abstract][Full Text] [Related]
15. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
Han C; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
[TBL] [Abstract][Full Text] [Related]
16. Management of chronic hepatitis B infection.
Sundaram V; Kowdley K
BMJ; 2015 Oct; 351():h4263. PubMed ID: 26491030
[TBL] [Abstract][Full Text] [Related]
17. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
[TBL] [Abstract][Full Text] [Related]
18. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.
Mao QG; Liang HQ; Yin YL; Tang JM; Yang JE; Wu CC; Chen Y; Zhang MY; Liu YY; Zheng XT; Zhuang LY; Chen SD
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101758. PubMed ID: 34303003
[TBL] [Abstract][Full Text] [Related]
20. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination.
Kim MN; Han KH; Ahn SH
Semin Oncol; 2015 Apr; 42(2):316-28. PubMed ID: 25843736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
